Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Free Cash Flow (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Free Cash Flow data on record, last reported at -$274.7 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 97.27% year-over-year to -$274.7 million; the TTM value through Dec 2025 reached -$899.6 million, down 60.93%, while the annual FY2025 figure was -$899.6 million, 60.93% down from the prior year.
  • Free Cash Flow reached -$274.7 million in Q4 2025 per RVMD's latest filing, down from -$198.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$35.4 million in Q2 2021 and bottomed at -$274.7 million in Q4 2025.
  • Average Free Cash Flow over 5 years is -$109.8 million, with a median of -$86.1 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: fell 10.67% in 2023, then plummeted 157.3% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$40.4 million in 2021, then plummeted by 49.46% to -$60.5 million in 2022, then crashed by 103.27% to -$122.9 million in 2023, then decreased by 13.32% to -$139.2 million in 2024, then crashed by 97.27% to -$274.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$274.7 million in Q4 2025, -$198.0 million in Q3 2025, and -$229.7 million in Q2 2025.